CME Information

LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

• Summarize the key points of the updated 2019 GOLD guidelines
• Discuss exacerbations and their impact on morbidity and mortality in COPD, and approaches to management
• Discuss when to refer patients in a timely fashion and develop a multidisciplinary plan for continuity of care between primary care and pulmonology clinics for patients with COPD
• Review how and when to consider emphysema assessment
• Explain how inhaler misuse, underuse, nonuse, and patient confusion and attitudes regarding inhalers impact compliance to therapy
• Consider inhalers based on inhaler attributes and patient preferences
• Demonstrate proper use of inhalers and assess at each visit for every patient with COPD
• Review the single- and fixed-dose dual and triple therapy combination pharmacologic options for the management of COPD and drug delivery considerations

ACTIVITY FACULTY
Barbara Yawn, MD, MSc
Chief Science Officer, COPD Foundation
Primary Care Physician, University of Minnesota

Byron M. Thomashow, MD
Chief Medical Officer, COPD Foundation
Professor of Medicine, Columbia University Medical Center

ACCREDITED PROVIDER
This activity is provided by The France Foundation.

TARGET AUDIENCE
This educational initiative is intended for primary care clinicians, pulmonologists, respiratory nurses and therapists, and other healthcare professionals who provide care for patients and families living with COPD.

STATEMENT OF NEED
Managing the complexities of COPD, along with comorbidities—often within brief office visits—is challenging. Some 16 million individuals in the United States are estimated to have COPD and another 12 million may remain undiagnosed. COPD is also frequently underdiagnosed, particularly in its early stages. Primary care practices are the backbone of COPD identification and management and have many continuing opportunities to update and upgrade the care they give to patients and families with COPD.

ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians: The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Content Creators
The following faculty report that they have relevant financial relationships to disclose:

• Dr. Barbara Yawn serves on advisory boards for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, and Pfizer, Inc.
• Dr. Byron Thomashow serves on advisory boards for AstraZeneca and GlaxoSmithKline.

DISCLOSURE OF UNLABELED USE
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This educational activity is supported by an educational grant from GlaxoSmithKline.

DISCLAIMER
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy-policy.

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.